On November 25, 2025 Immorta Bio Inc., a scientific longevity company pioneering therapies focusing on Treating Diseases of Aging and Treating Aging as Disease, reported the publication of its international patent application PCT/WO2025184665[1], entitled "Senescence Vaccine."
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The application describes Immorta Bio’s proprietary approach to stimulating the immune system to selectively eliminate senescent cells: the dysfunctional "old cells" that drive aging, inflammation, organ failure, and support tumor growth. Removing these harmful cells results in a broad anti-aging effect throughout the body while simultaneously inhibiting cancer progression, addressing two major root causes of age-related decline:
accumulation of damage, and
loss of regenerative capacity.
At the center of the patent is SenoVax, Immorta Bio’s first-in-class senolytic immunotherapy, which has demonstrated potent reduction of lung, breast, brain, skin, and pancreatic cancers in established in vivo models[2]. SenoVax is also the subject of FDA submission of IND #30745 for advanced lung cancer[3].
"SenoVax is a true first-in-class immunotherapy," said Dr. Thomas Ichim, President and Chief Scientific Officer of Immorta Bio, and inventor on 26 of the company’s patent applications. "By killing senescent cells, we reduce aging biology itself while simultaneously disrupting the tumor-supportive microenvironment required for cancer survival."
Immorta Bio’s broader longevity strategy combines SenoVax with StemCellRevivify, the company’s platform for introducing young, organ-specific progenitor and mesenchymal stem cells to restore regenerative capacity. Together, the two platforms target the two fundamental drivers of aging — impaired clearance of damaged cells and loss of tissue regeneration.
"Cancer is the most prevalent disease of aging, and SenoVax allows us to attack both aging biology and tumor biology at the same time," said Dr. Boris Reznik, Chairman and CEO of Immorta Bio. "Our clinical goal is to first establish safety and efficacy in advanced cancer patients and then expand into age-related conditions and ultimately into treating aging itself."
Immorta Bio’s preclinical work shows compelling evidence across:
multiple cancer models
aging and frailty models
organ-failure models
>100% extension of lifespan and improvement in healthspan
These results, along with the publication of this PCT application, strengthen Immorta Bio’s position as the only company developing a dual-platform solution to aging that also treats its most lethal diseases.
(Press release, Immorta Bio, NOV 25, 2025, View Source [SID1234660952])